comparemela.com

Latest Breaking News On - Moneycontrol sakshi batra - Page 1 : comparemela.com

3 Point Analysis | Watch latest Videos on 3 Point Analysis

January 04, 2021 06:46 PM IST The Drug Controller General of India (DCGI) on January 3 granted permission for restricted emergency use of the AstraZeneca-Oxford University and Bharat Biotech Covid-19 vaccines. The approval was based on the recommendations of the Subject Expert Committee (SEC), which reviewed the data on safety and immunogenicity of the two vaccines. However, post the announcement it is India’s indigenous vaccine which has found itself in the middle of a controversy. Here’s why. January 01, 2021 05:18 PM IST All calls from Reliance Jio to other networks in India to be free from January 1, as the Interconnect Usage Charge (IUC) regime ends. Moneycontrol s Sakshi Batra does a 3 -Point Analysis to find out what this means for the industry at large

Editor s Take | Watch latest Videos on Editor s Take

Follow us on: ->->Moneycontrol/MC News/MC News Internal Category Native 5|~|Moneycontrol/MC News/MC News Internal Health 300x600|~|Moneycontrol/MC News/MC News Internal Category 300x250 Networth|~|Moneycontrol/MC News/MC News Internal Health 728x90|~|Moneycontrol/MC ROS/MC ROS Slider 2x2|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News Internal 300x250 Middle 5|~|Moneycontrol Mobile WAP/MC WAP ROS/MC WAP ROS Audio 1x1|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News INTEL MICROSITE 320x50|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News flying carpet 300x600 1|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News Internal Masthead 300x250

Reporter s Take | Watch latest Videos on Reporter s Take

Follow us on: ->->Moneycontrol/MC News/MC News Internal Category Native 5|~|Moneycontrol/MC News/MC News Internal Health 300x600|~|Moneycontrol/MC News/MC News Internal Category 300x250 Networth|~|Moneycontrol/MC News/MC News Internal Health 728x90|~|Moneycontrol/MC ROS/MC ROS Slider 2x2|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News Internal 300x250 Middle 5|~|Moneycontrol Mobile WAP/MC WAP ROS/MC WAP ROS Audio 1x1|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News INTEL MICROSITE 320x50|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News flying carpet 300x600 1|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News Internal Masthead 300x250

Ideas for Profit | Watch latest Videos on Ideas for Profit

Bulk drug manufacturer, Bajaj Healthcare, had a robust Q3 with profits more than tripling to Rs 26 crore. Here s a detailed analysis of Bajaj s Q3 performance, its future outlook and whether investors should keep the stock on their radar March 23, 2021 09:16 PM IST Gabriel India is the leading supplier of shock absorbers & front forks to all major manufacturers of 2,3 & 4 wheelers in India. A shift in preference towards personal transport as people continue to be cautious about taking public vehicles is a key growth trigger for Gabriel as it generates more than 89% of its revenues from these segments. It has launched 11 product lines which received a positive market response. The company sees significant opportunities in export markets as US and the European OEMs have started reducing their dependence on Chinese manufacturers for component supplies. The company has established itself as a strong player in the global market. Watch the video for more updates

Millennial Pulse | Watch latest Videos on Millennial Pulse

Follow us on: ->->Moneycontrol/MC News/MC News Internal Category Native 5|~|Moneycontrol/MC News/MC News Internal Health 300x600|~|Moneycontrol/MC News/MC News Internal Category 300x250 Networth|~|Moneycontrol/MC News/MC News Internal Health 728x90|~|Moneycontrol/MC ROS/MC ROS Slider 2x2|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News Internal 300x250 Middle 5|~|Moneycontrol Mobile WAP/MC WAP ROS/MC WAP ROS Audio 1x1|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News INTEL MICROSITE 320x50|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News flying carpet 300x600 1|~|Moneycontrol Mobile WAP/MC WAP News/MC WAP News Internal Masthead 300x250

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.